Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 11/20 | 0.46 |
| ▸ | PDE4A | P27815 | 11/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 6/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802757 | 0.89 | SYK (0.44) | ROCK2ROCK1SYKGPR6 | |
| SCHEMBL6796678 | 0.83 | NR2F2 (0.48) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10468175 | 0.79 | ROCK2 (0.48) | ROCK2ROCK1SYK | |
| SCHEMBL6797586 | 0.79 | TRPA1 (0.45) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10468298 | 0.77 | ROCK2 (0.43) | ROCK2ROCK1SYK | |
| SCHEMBL6797210 | 0.74 | KMT2A (0.48) | ROCK2ROCK1 | |
| SCHEMBL4514203 | 0.74 | TSHR (0.48) | ROCK2 | |
| SCHEMBL6801980 | 0.73 | HPGD (0.37) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15635822 | 0.72 | GPR6 (0.43) | PDE4APDE4BPDE4CPDE4DGPR6 | |
| SCHEMBL10169541 | 0.71 | BTK (0.40) | ROCK2ROCK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825199-B2 | 7-Substituted quinazolin-2,4-diones useful as antibacterial agents | WARNER-LAMBERT COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | disclosed |
| US-6331538-B1 | TREATMENT OF BACTERIAL INFECTION | WARNER-LAMBERT COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1028950-A1 | NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999021840-A1 | NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | NQO2, TOP1, TOP2A | CHRM3 4539/4885PDE4A 521/4885PDE4B 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.